We’re proud to be one of this year’s sponsors of the European Competence Network on Mastocytosis (ECNM) annual meeting. The team is here and looking forward to connecting with systemic #mastocytosis disease experts. #NonAdvSM #AdvSM
Cogent Biosciences
Biotechnology Research
Waltham, Massachusetts 14,003 followers
Precision therapeutics for genetically defined diseases. Real solutions for real challenges.
About us
Cogent Biosciences is a biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent’s lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Bezuclastinib has already exhibited promising early clinical activity and safety in a Phase 1/2 trial in patients with advanced GIST and also has the potential to fill an unmet need for patients living with Systemic Mastocytosis.
- Website
-
http://www.cogentbio.com
External link for Cogent Biosciences
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Waltham, Massachusetts
- Type
- Public Company
- Founded
- 2014
- Specialties
- gastrointestinal stromal tumors (GIST), Oncology, Systemic Mastocytosis, and kinase inhibitors
Locations
-
Primary
Get directions
275 Wyman Street
3rd Floor
Waltham, Massachusetts 02451, US
-
Get directions
4840 Pearl East Circle
Suite 100
Boulder, Colorado 80301, US
Employees at Cogent Biosciences
Updates
-
Tune in next week on Wed, Sept 3 at 9:00am ET to listen to our fireside chat at Citi’s 2025 Biopharma Back-to-School Conference. Register and join here http://bit.ly/3HFbBDF.
-
-
Today we reported our financial results for the second quarter of 2025. It’s been an exciting year at Cogent and there’s still lots to look forward to as we prepare for two more pivotal trial readouts in GIST and AdvSM in the second half. Check out the release here: http://bit.ly/4fshBvU
-
-
Every year on July 13th, we recognize #GISTAwarenessDay—a day dedicated to raising awareness, advancing education, and supporting those affected by Gastrointestinal Stromal Tumors (GIST). At Cogent, we’re proud to partner with the The Life Raft Group and others in the GIST community to support individuals and families impacted by this rare cancer. We’re committed to driving meaningful change in the lives of those living with #GIST.
-
-
Today we reported positive top-line results from Part 2 of our SUMMIT trial in #NonAdvSM achieving statistical significance across all primary and key secondary endpoints. Read the release here: https://bit.ly/40Fqr39. Our webcast will begin this morning at 8am ET. We invite you to join here: bit.ly/4kmOYkJ. We are grateful for the dedication of the patients, families, caregivers and investigators who have enabled us to reach this milestone.
-
-
Please note our new presentation time: 8:10am ET, Thursday, June 5 at the Jefferies Global Healthcare Conference. Register and listen in here: https://bit.ly/4kz93Va
-
-
Join us on Thursday at 7:35am ET for our presentation at the Jefferies Global Healthcare Conference. Register and listen in here: https://bit.ly/4kz93Va
-
-
This April, we extended Wellness Week into a month-long celebration of healthy living. Throughout the month, our team engaged in group exercises, healthy eating, and creative wellness projects, making it an inspiring experience for all. Thank you to everyone who participated! 🌸 🏃 🥗 #WellnessMonth #HealthyLiving
-